secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-05-14T20:28:56+00:00
Accession:  0001193125-26-224156
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics reports Q1 2026 net loss of $27.7M, highlights 100% CR rate in TPST-2003 trials
--------------------------------------------------------------------------------

- Ended Q1 with $1.8M cash vs $7.7M at year-end 2025; net loss $27.7M ($2.53/share) vs $10.9M ($3.16) year ago.
- TPST-2003 showed 100% complete response in 15 CAR-T-naïve evaluable patients across two trials; no Grade ≥3 CRS/ICANS.
- Selected Cincinnati Children's AGCTC as lead manufacturing partner; lentiviral vector received for TPST-2003.
- Appointed Andrew Fang, Ph.D., as Head of Business Development to lead partnerships and licensing.
- Completed asset acquisition of dual-targeting CAR-T assets from Factor Bioscience and Erigen; $6M private placement closed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526224156/0001193125-26-224156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526224156/tpst-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-224156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer